Inogen Résultats passés
Passé contrôle des critères 0/6
Les bénéfices de Inogen ont diminué à un taux annuel moyen de -10.1%, tandis que le secteur Medical Equipment a vu ses bénéfices augmenter de en à 13.6% par an. Les revenus ont augmenté de en baisse à un taux moyen de 0.3% par an.
Informations clés
-10.07%
Taux de croissance des bénéfices
-8.78%
Taux de croissance du BPA
| Medical Equipment Croissance de l'industrie | 8.90% |
| Taux de croissance des recettes | -0.29% |
| Rendement des fonds propres | -13.61% |
| Marge nette | -7.08% |
| Dernière mise à jour des bénéfices | 31 Mar 2026 |
Mises à jour récentes des performances passées
Recent updates
Mise à jour du récit • May 09
INGN: Bullish Initiation And Buyback Program Will Support Future Upside
Analysts have trimmed their price target on Inogen from about $13.00 to roughly $12.67, reflecting updated assumptions around revenue, profit margins and future P/E following fresh bullish initiation research from the Street. Analyst Commentary Analysts are using the fresh bullish initiation as a chance to refresh their models, focus on execution and reassess how much they are willing to pay for Inogen at the current P/E.
Mise à jour du récit • Apr 19
INGN: Buybacks And New Leadership Will Support Future Returns
Analysts have adjusted their price target on Inogen to $12.00, reflecting updated views on revenue growth assumptions, profit margin expectations, and the valuation multiple following recently published Street research, including a positive initiation of coverage. Analyst Commentary Recent Street research on Inogen has combined a constructive long term narrative with a more restrained tone on execution risks and how much investors are currently being asked to pay for that story.Mise à jour du récit • Apr 04
INGN: Sleep Therapy Expansion And Buybacks Will Support Future Returns
Analysts have adjusted their price target on Inogen to $12.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, which keep the fair value view broadly in line with prior estimates. What's in the News Inogen appointed Jason Richardson as Chief Financial Officer, effective April 6, 2026, succeeding Michael Bourque, who will remain in an advisory role until June 30, 2026 (Key Developments).Mise à jour du récit • Mar 21
INGN: Sleep Therapy Expansion And Buybacks Will Support Future Earnings Power
Analysts have maintained their price target for Inogen at $12.00, making small adjustments to assumptions around the discount rate, revenue growth, profit margin, and future P/E, which together result in an unchanged fair value view. What's in the News Inogen approved a share repurchase program of up to US$30 million of its common stock, funded by cash flow and existing cash reserves, with an expiry on the earlier of December 31, 2027, or when the full amount is used (Key Developments).Mise à jour du récit • Mar 06
INGN: Sleep Therapy Expansion And Buybacks Will Support Future Undervalued Upside
Analysts maintained their fair value estimate for Inogen at $13.00, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E that refine rather than significantly change their prior view. What's in the News Inogen announced a share repurchase program authorizing the company to buy back up to US$30 million of its common stock, funded by cash flow and existing cash reserves, with the program running until the earlier of December 31, 2027, or when the full amount is used (Key Developments).Mise à jour du récit • Feb 20
INGN: Sleep Therapy Portfolio Expansion Will Support Future Earnings Power
Analysts have adjusted their price target on Inogen to $12.00. The change reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations.Mise à jour du récit • Feb 06
INGN: Sleep Therapy Expansion Will Support Future Confidence In Undervalued Shares
Analysts have kept their price target for Inogen steady at US$13.00. This reflects only minor tweaks to assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock.Mise à jour du récit • Jan 22
INGN: Sleep Therapy Expansion Will Support Future Earnings Power Ahead
Narrative Update on Inogen Analysts have modestly adjusted their price target on Inogen to reflect updated assumptions for discount rate, revenue growth, profit margin and future P/E. This has led to a refined valuation that still centers around a fair value of $12.00 per share.Mise à jour du récit • Jan 08
INGN: Stable Guidance And New Respiratory Line Will Support Future Confidence
Analysts have kept their price target for Inogen broadly in line with prior views, with only a small adjustment supported by updated assumptions around discount rate, profit margin and future P/E expectations, rather than any major shift in the outlook. What's in the News Inogen launched Aurora CPAP masks as a new product line within its respiratory care portfolio, targeting patients with obstructive sleep apnea through the F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows range (Key Developments).Mise à jour du récit • Dec 16
INGN: Rising Revenue Outlook Will Support Stronger Earnings Power Ahead
Analysts have raised their price target on Inogen by approximately $5 to around $12 per share, reflecting modestly higher expectations for revenue growth, profit margins, and future earnings multiples, despite a slightly higher assumed discount rate. What's in the News Issued new fourth quarter 2025 revenue guidance of $87 million to $90 million, implying roughly 10% year over year growth at the midpoint compared to fourth quarter 2024 (company guidance) Reiterated full year 2025 revenue outlook of $354 million to $357 million, targeting about 6% growth at the midpoint versus 2024 revenue (company guidance) Emphasized that the updated outlook reflects confidence in execution while maintaining a disciplined view of demand and pricing conditions in the portable oxygen concentrator market (company guidance) Valuation Changes The fair value estimate has risen materially, increasing from approximately $7.00 to $12.00 per share.Mise à jour du récit • Dec 02
INGN: Guidance Stability Will Drive Confidence As Margins Poised To Improve
Analysts have maintained their price target for Inogen at $13.00. This reflects minimal changes in financial assumptions and a steady outlook for the company's revenue growth and profitability.Mise à jour du récit • Nov 18
INGN: Profit Margins Will Strengthen As Revenue Guidance Remains Encouraging
Analysts have adjusted Inogen’s price target to $13.00. This is a slight change that reflects expectations of improved profit margins, despite modest revisions in growth rates and valuation metrics.Seeking Alpha • Nov 11
Slow Progress At Inogen ... But Progress All The Same
Summary Inogen (INGN) continues its turnaround, showing progress in revenue growth and margins, but the pace remains slower and riskier than the market desires. INGN posted positive adjusted EBITDA and raised full-year guidance, despite mixed quarterly results and ongoing volatility in direct-to-consumer and rental segments. The company’s strong market position, new product launches, and partnerships offer long-term growth potential, especially as patients consistently prefer portable solutions. Valuation appears deeply discounted, with net cash and little credit for progress; INGN offers speculative upside for risk-tolerant investors if improvements persist. Read the full article on Seeking AlphaMise à jour du récit • Nov 03
INGN: Profit Margins Will Strengthen Amid Broader Respiratory Care Market Expansion
Analysts have slightly increased their price target for Inogen to $13.00 per share. This change reflects modest adjustments to profit margin forecasts and discount rates in their updated models.Mise à jour du récit • Oct 20
Home And Outpatient Respiratory Care Will Expand Market Opportunities
Analysts have reaffirmed their price target for Inogen at $13.00, citing stable outlooks with only minor adjustments to key financial metrics. What's in the News Inogen issued new earnings guidance for the third quarter of 2025, projecting revenue between $91 million and $93 million.Mise à jour du récit • Oct 05
Home And Outpatient Respiratory Care Will Expand Market Opportunities
Analysts have raised their price target for Inogen from $11.00 to $13.00, citing updated projections of slightly stronger revenue growth and reduced discount rates as key contributors to the increased valuation. What's in the News Inogen, Inc.Article d’analyse • Aug 31
There's No Escaping Inogen, Inc.'s (NASDAQ:INGN) Muted Revenues Despite A 29% Share Price Rise
The Inogen, Inc. ( NASDAQ:INGN ) share price has done very well over the last month, posting an excellent gain of 29...Mise à jour du récit • Aug 10
Home And Outpatient Respiratory Care Will Expand Market Opportunities
Despite an upward revision in revenue growth forecasts and a lower future P/E, the analyst consensus price target for Inogen has decreased from $11.67 to $11.00, indicating increased caution around the company’s fair value. What's in the News Inogen expects third quarter 2025 revenue of $91–93 million (~4% YoY growth) and full-year 2025 revenue of $354–357 million (~6% YoY growth).Article d’analyse • May 10
Analysts Have Been Trimming Their Inogen, Inc. (NASDAQ:INGN) Price Target After Its Latest Report
A week ago, Inogen, Inc. ( NASDAQ:INGN ) came out with a strong set of quarterly numbers that could potentially lead to...
Nouveau récit • Apr 01
Yuwell Collaboration Will Open Chinese Respiratory Market
Strategic partnerships and product innovation in China and digital health are expected to drive growth and improve earnings potential.Article d’analyse • Mar 08
Why Investors Shouldn't Be Surprised By Inogen, Inc.'s (NASDAQ:INGN) 35% Share Price Plunge
Inogen, Inc. ( NASDAQ:INGN ) shareholders won't be pleased to see that the share price has had a very rough month...Seeking Alpha • Mar 01
A Volatile Share Price Masks Some Of The Progress At Inogen
Summary Inogen's new management and strategy are yielding results, with better-than-expected 2024 performance and a more stable base from which to keep growing the B2B business. Despite weak DTC sales, strong B2B growth drove better-than-expected sales in Q4, and Inogen likewise beat on margins. Guidance disappointed investors and prompted a 15% drop in the shares, as moderately better revenue guidance was offset by unexpected gross margin deleverage. Key recent developments include FDA approval of the Simeox device and a strategic partnership with Yuwell, both offering long-term growth potential but requiring time to ramp. While 2024 progress is promising and the valuation is not at all demanding, significant risks remain, particularly in revenue acceleration and margin leverage, making Inogen a high-risk but intriguing speculative investment. Read the full article on Seeking AlphaArticle d’analyse • Feb 28
Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00
Shareholders in Inogen, Inc. ( NASDAQ:INGN ) had a terrible week, as shares crashed 23% to US$7.95 in the week since...Article d’analyse • Jan 22
Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 32%
Inogen, Inc. ( NASDAQ:INGN ) shareholders would be excited to see that the share price has had a great month, posting a...Seeking Alpha • Sep 24
Inogen: Upside Seems Limited After Big Move Up
Summary Inogen, Inc. manufactures portable oxygen concentrators and related accessories. The shares have doubled over the past year, but the equity is still trading at roughly 75% of annual sales. Despite an earnings beat in Q2, Wall Street analysts are cautious about the stock's current prospects. Inogen boasts a strong balance sheet with over $120 million in cash (which is roughly half the stock's market cap) and no long-term debt. An analysis of Inogen follows in the paragraphs below. Read the full article on Seeking AlphaArticle d’analyse • Jul 16
Inogen, Inc.'s (NASDAQ:INGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%
Despite an already strong run, Inogen, Inc. ( NASDAQ:INGN ) shares have been powering on, with a gain of 26% in the...Seeking Alpha • Jul 01
Inogen: Improving, But Still Struggling For Air
Summary Inogen aims to help millions suffering from COPD with portable oxygen delivery machines, but its financial performance has been inconsistent. Inogen faced execution issues, but recent improvements in operating momentum due to competitor exits and new management team are sparking optimism. Recent revenue growth, cost cuts, and narrowing losses are encouraging, but shares remain highly speculative and further progress is needed for a more positive outlook. Read the full article on Seeking AlphaArticle d’analyse • May 22
Inogen, Inc. (NASDAQ:INGN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry
Inogen, Inc. ( NASDAQ:INGN ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last...Seeking Alpha • Apr 13
Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities
Summary Inogen has continued to struggle, with growth in the rental business overshadowed by declines in direct-to-consumer sales, volatility in business-to-business sales, and pricing pressures. Inogen has the opportunity to leverage the exit of a major competitor, Philips, from the portable oxygen concentrator (POC) market. The new management team aims to position Inogen as the premium POC provider and partner with home medical equipment companies, while also focusing on the Physio-Assist opportunity. Inogen shares trade at a steep discount, but the Street typically wants nothing to do with low-growth small-cap med-tech, so management must present a credible plan for meaningful sustained growth. Read the full article on Seeking AlphaArticle d’analyse • Mar 01
Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target
There's been a major selloff in Inogen, Inc. ( NASDAQ:INGN ) shares in the week since it released its annual report...Article d’analyse • Feb 01
Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%
Despite an already strong run, Inogen, Inc. ( NASDAQ:INGN ) shares have been powering on, with a gain of 25% in the...Ventilation des recettes et des dépenses
Ventilation des recettes et des dépenses
Comment Inogen gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.
Historique des gains et des recettes
| Date | Recettes | Les revenus | Dépenses G+A | Dépenses de R&D |
|---|---|---|---|---|
| 31 Mar 26 | 351 | -25 | 164 | 20 |
| 31 Dec 25 | 349 | -23 | 163 | 19 |
| 30 Sep 25 | 347 | -25 | 165 | 20 |
| 30 Jun 25 | 343 | -26 | 168 | 19 |
| 31 Mar 25 | 340 | -27 | 169 | 19 |
| 31 Dec 24 | 336 | -36 | 172 | 22 |
| 30 Sep 24 | 332 | -53 | 174 | 22 |
| 30 Jun 24 | 327 | -92 | 170 | 23 |
| 31 Mar 24 | 322 | -97 | 168 | 22 |
| 31 Dec 23 | 316 | -102 | 170 | 21 |
| 30 Sep 23 | 328 | -133 | 170 | 20 |
| 30 Jun 23 | 349 | -96 | 178 | 20 |
| 31 Mar 23 | 369 | -90 | 182 | 22 |
| 31 Dec 22 | 377 | -84 | 180 | 22 |
| 30 Sep 22 | 366 | -50 | 179 | 21 |
| 30 Jun 22 | 353 | -28 | 170 | 20 |
| 31 Mar 22 | 351 | -20 | 167 | 18 |
| 31 Dec 21 | 358 | -6 | 162 | 17 |
| 30 Sep 21 | 356 | 11 | 155 | 16 |
| 30 Jun 21 | 337 | -2 | 147 | 15 |
| 31 Mar 21 | 307 | -5 | 136 | 14 |
| 31 Dec 20 | 308 | -6 | 136 | 14 |
| 30 Sep 20 | 313 | -2 | 135 | 14 |
| 30 Jun 20 | 331 | 6 | 136 | 13 |
| 31 Mar 20 | 360 | 14 | 141 | 11 |
| 31 Dec 19 | 362 | 21 | 142 | 9 |
| 30 Sep 19 | 370 | 32 | 144 | 8 |
| 30 Jun 19 | 373 | 42 | 148 | 7 |
| 31 Mar 19 | 369 | 46 | 144 | 7 |
| 31 Dec 18 | 358 | 52 | 134 | 7 |
| 30 Sep 18 | 335 | 41 | 120 | 7 |
| 30 Jun 18 | 309 | 32 | 107 | 6 |
| 31 Mar 18 | 276 | 26 | 96 | 5 |
| 31 Dec 17 | 249 | 21 | 88 | 5 |
| 30 Sep 17 | 237 | 27 | 81 | 5 |
| 30 Jun 17 | 222 | 25 | 76 | 5 |
| 31 Mar 17 | 212 | 24 | 72 | 5 |
| 31 Dec 16 | 203 | 21 | 69 | 5 |
| 30 Sep 16 | 192 | 19 | 67 | 5 |
| 30 Jun 16 | 179 | 17 | 64 | 5 |
| 31 Mar 16 | 168 | 13 | 60 | 4 |
| 31 Dec 15 | 159 | 12 | 57 | 4 |
| 30 Sep 15 | 148 | 9 | 53 | 4 |
| 30 Jun 15 | 136 | 9 | 49 | 3 |
Des revenus de qualité: INGN n'est actuellement pas rentable.
Augmentation de la marge bénéficiaire: INGN n'est actuellement pas rentable.
Analyse des flux de trésorerie disponibles par rapport aux bénéfices
Analyse de la croissance passée des bénéfices
Tendance des revenus: INGN n'est pas rentable et les pertes ont augmenté au cours des 5 dernières années à un rythme de 10.1% par an.
Accélération de la croissance: Impossible de comparer la croissance des bénéfices de INGN au cours de l'année écoulée à sa moyenne sur 5 ans car elle n'est actuellement pas rentable
Bénéfices par rapport au secteur d'activité: INGN n'est pas rentable, ce qui rend difficile la comparaison de sa croissance des bénéfices de l'année écoulée avec celle du secteur Medical Equipment ( 14.8% ).
Rendement des fonds propres
ROE élevé: INGN a un retour sur capitaux propres négatif ( -13.61% ), car il n'est actuellement pas rentable.
Rendement des actifs
Rendement des capitaux employés
Découvrir des entreprises performantes dans le passé
Analyse de l'entreprise et données financières
| Données | Dernière mise à jour (heure UTC) |
|---|---|
| Analyse de l'entreprise | 2026/05/25 04:27 |
| Cours de l'action en fin de journée | 2026/05/22 00:00 |
| Les revenus | 2026/03/31 |
| Revenus annuels | 2025/12/31 |
Sources de données
Les données utilisées dans notre analyse de l'entreprise proviennent de S&P Global Market Intelligence LLC. Les données suivantes sont utilisées dans notre modèle d'analyse pour générer ce rapport. Les données sont normalisées, ce qui peut entraîner un délai avant que la source ne soit disponible.
| Paquet | Données | Cadre temporel | Exemple de source américaine * |
|---|---|---|---|
| Finances de l'entreprise | 10 ans |
| |
| Estimations consensuelles des analystes | +3 ans |
|
|
| Prix du marché | 30 ans |
| |
| Propriété | 10 ans |
| |
| Gestion | 10 ans |
| |
| Principaux développements | 10 ans |
|
* Exemple pour les titres américains ; pour les titres non américains, des formulaires réglementaires et des sources équivalentes sont utilisés.
Sauf indication contraire, toutes les données financières sont basées sur une période annuelle mais mises à jour trimestriellement. C'est ce qu'on appelle les données des douze derniers mois (TTM) ou des douze derniers mois (LTM). En savoir plus.
Modèle d'analyse et flocon de neige
Les détails du modèle d’analyse utilisé pour générer ce rapport sont disponibles sur notre page Github; nous proposons également des guides expliquant comment utiliser nos rapports et des tutoriels sur Youtube.
Découvrez l'équipe de classe mondiale qui a conçu et construit le modèle d'analyse Simply Wall St.
Indicateurs de l'industrie et du secteur
Nos indicateurs de secteur et de section sont calculés toutes les 6 heures par Simply Wall St. Les détails de notre processus sont disponibles sur Github.
Sources des analystes
Inogen, Inc. est couverte par 9 analystes. 3 de ces analystes ont soumis les estimations de revenus ou de bénéfices utilisées comme données d'entrée dans notre rapport. Les soumissions des analystes sont mises à jour tout au long de la journée.
| Analyste | Institution |
|---|---|
| Anderson Schock | B. Riley Securities, Inc. |
| Ilya Zubkov | Freedom Broker |
| Matthew Mishan | KeyBanc Capital Markets Inc. |